La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aptorum Gr a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aptorum Gr..

Aptorum Gr (NASDAQ:APM) Azioni, Catena delle Opzioni

Aptorum Gr

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

apM Coin

MORIEN RESOURCES CORP ORD by Morien Resources Corp.

Morien Resources Corp

EAGLE GRAPHITE INC by Eagle Graphite Inc.

APM HUMAN SVCS INTL PTY by APM HUMAN SVCS INTL PTY LTD.

ApartmentLove Inc

ASPERMONT LTD by ASPERMONT LTD.

Amper SA

Aperam SA

APERAM ORD

Trust for Professional Managers ActivePassive Intermediate Municipal Bond ETF

Mark Cuban is an outspoken billionaire and part-owner of the Dallas Mavericks but also one of the most vocal critics of the former president. He has used terms like &#8220;fascist&#8221; to describe Trump&#8217;s behavior. However, Cuban was recently seen on ABC justifying his business relationship with Miriam Adelson, who gave Trump an astounding $100 million to support his 2024 election campaign.
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Adelson&#8217;s hefty donation to Trump – the largest of any sports team owner – shows she's all-in on Trump's campaign. That has made things somewhat awkward for Cuban, considering his loud and clear support for Kamala Harris, who is running against Trump.
Yet, when asked how he felt about this partnership, Cuban brushed off the issue. &#8220;Do you know how everyone is voting who you work with? Do you know how the owners of your company are voting? This is America. People get to choose their candidates and vote for who they want, which makes it amazing,&#8221; Cuban said in an interview. Cuban&#8217;s message is that differing political views shouldn't interfere with running a business.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Cuban also pointed out that he's not giving money to Harris – or any other political candidate, for that matter. Despite his <a href="https://www.benzinga.com/news/24/09/40745014/kamala-harris-is-pro-business-mark-cuban-says-vice-presidents-centre-100-policies-differ-from-bidens">vocal support for the current vice president</a>, Cuban hasn&#8217;t donated a penny to her campaign. He believes in making a difference through his words and influence instead of writing checks.
He's been on social media defending Harris and has engaged in fiery debates, <a href="https://www.benzinga.com/markets/equities/24/10/41568486/mark-cuban-highlights-trumps-potential-to-ruin-christmas-but-he-might-also-end-up-spoiling-the-p">calling out Trump's behavior</a> as dangerous and out of touch. Cuban also stated in the same ABC interview that &#8220;Donald Trump is not a normal candidate,&#8221; claiming that he has used divisive language and taken actions that, in Cuban&#8217;s opinion, verge on authoritarianism.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
Despite clashing ideologies, Cuban seems comfortable keeping his business relationships and political beliefs separate. Miriam Adelson, who inherited a vast fortune from her late husband Sheldon Adelson, now <a href="https://www.benzinga.com/news/23/12/36231225/mark-cuban-to-retain-25-stake-in-dallas-mavericks-after-sale-to-adelson-family-report">shares ownership of the Mavericks with Cuban</a>. The Adelson family is deeply involved in politics and their support of Trump hasn't wavered. On the other hand, Cuban is sticking to his guns – supporting Harris in the media and making the case for what he believes is best for the country.
At the end of the day, Cuban seems determined to stay true to his political convictions and his business partnerships. &#8220;This is America,&#8221; he says – a place where people can disagree, even sharply and still find ways to work together.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Startups

'This Is America,' Mark Cuban Says, Justifying His Business Relationship With Trump's $100M Megadonor And Mavericks Co-Owner

<a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-">Kevin O'Leary</a>, best known from Shark Tank, has backed Elon Musk's sweeping $2 trillion plan to slash federal spending. With former President Donald Trump's backing, Musk is proposed to head the Department of Government Efficiency (DOGE) if Trump secures a second term.&nbsp;
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
O'Leary enthusiastically remarked on Fox News, "Release the hounds" about unleashing Musk's cost-cutting skills across federal agencies. "Let them in there and come back with a shopping list of ideas and let's debate it. Why not? We need to find some savings."
In O'Leary's view, the U.S. federal government is "the biggest business in America." He sees Musk, the mind behind Tesla and SpaceX, as uniquely equipped to tackle this budget behemoth.&nbsp;
"Who has the executional skills and the track record to even look at this problem?" he said, emphasizing that Musk's focus and determination make him an ideal candidate. Indeed, O'Leary believes that Musk's efficiency ethos, which has driven companies like SpaceX to success, would transfer seamlessly to federal budget cuts – an area few entrepreneurs would tread.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Musk has clarified that he views today's government spending as unsustainable, especially with national debt interest payments now outstripping the defense budget.&nbsp;
Speaking at a Trump rally, he linked federal spending to inflation and increased taxes, which he warned are squeezing <a href="https://www.benzinga.com/personal-finance/24/08/40582239/californias-new-plan-taxpayers-might-soon-be-funding-home-loans-for-illegal-migrants-heres-what-">taxpayers </a>dry. With his proposal to shave off $2 trillion, Musk aims to start the work he sees as vital for long-term economic stability.
But this grand vision has detractors. Some experts question whether cutting a third of federal spending is possible without compromising essential services.&nbsp;
Analysis from the Washington Post noted that Musk&#8217;s cuts could gut programs like health care, food security and housing, impacting millions of Americans. Even previously untouchable sectors, such as Social Security and the military, may be affected.&nbsp;
See Also: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Musk acknowledged on X (formerly Twitter) that his proposed cuts could result in economic turmoil, suggesting that hard times would be ahead before any benefits emerged.
Still, O'Leary remains undeterred. He sees Musk's focus as an asset, contrasting the entrepreneur's "100% signal" approach with what he describes as other business leaders' focus on "noise." To O'Leary, Musk's dedication to his projects means he is all about the mission and not distracted by side issues, making him ideal for leading such a challenging initiative.&nbsp;
He even suggested that Musk go beyond the $2 trillion target. "We've got to go find $2 trillion; we've got to go find $5 trillion," O'Leary urged.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Kevin O'Leary Supports Elon Musk's $2 Trillion Plan To Slash Government Spending With Trump's Backing–'It's Time To Release The Hounds'

WIIM

COGT

Cogent Biosciences shares are trading lower after the company announced Bezuclantinib presentations at the 66th annual American Society of Hematology meeting.

RBC Capital analyst Sean Dodge reiterates IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and maintains $270 price target.

News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Outperform and raises the price target from $352 to $359.

Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Raises Price Target to $359

PRAA

PRA Group shares are trading higher after the company reported better-than-expected Q3 financial results. Additionally, Truist Securities maintained a Buy rating on the stock and raised its price target from $28 to $31.

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith reiterates Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Outperform and raises the price target from $82 to $90.

ROOT

Keefe, Bruyette & Woods Reiterates Outperform on Root, Raises Price Target to $90

CENX

Century Aluminum shares are trading higher after the company reported better-than-expected Q3 financial results and B.Riley Securities raised its price target on the stock from $22 to $24.

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $510 to $503.

VRTX

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $503

Diversified Healthcare Trust shares are trading lower after the company reported worse-than-expected Q3 financial results.

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Market Perform and lowers the price target from $210 to $198.

Keefe, Bruyette & Woods Maintains Market Perform on Meritage Homes, Lowers Price Target to $198

JP Morgan analyst Peter Peng maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Overweight and lowers the price target from $150 to $135.

SLAB

JP Morgan Maintains Overweight on Silicon Laboratories, Lowers Price Target to $135

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and raises the price target from $252 to $254.

ILMN

RBC Capital Maintains Outperform on Illumina, Raises Price Target to $254

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Market Perform and lowers the price target from $6 to $5.

Keefe, Bruyette & Woods Maintains Market Perform on Marqeta, Lowers Price Target to $5

SANA

Sana Biotechnology shares are trading lower after JMP Securities downgraded the stock from Market Outperform to Market Perform. Also, HC Wainwright & Co. lowered its price target from $11 to $8.

JP Morgan analyst Samik Chatterjee maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Underweight and lowers the price target from $34 to $32.

JP Morgan Maintains Underweight on Sensata Technologies, Lowers Price Target to $32

Keefe, Bruyette &amp; Woods analyst Vasundhara Govil maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and raises the price target from $97 to $102.

Keefe, Bruyette & Woods Maintains Outperform on Fidelity National Info, Raises Price Target to $102

DXPE

DXP Enterprises shares are trading higher after the company reported better-than-expected Q3 financial results.

The U.S. services sector's economic momentum is firing at all cylinders, with business activity in October reaching its strongest level <a href="https://www.benzinga.com/news/econ-s">in over two years.</a>
According to the Institute for Supply Management, the Services PMI surged to 56% in October 2024, up from 54.9% in September, defying expectations of a dip to 53.8%.
This result marks the fastest pace of expansion in the U.S. services sector since August 2022. The ISM Services PMI has shown growth in 20 of the past 22 months since January 2023, with October's reading standing 3.7 percentage points above the 2024 average of 52.3%.
&#8220;The increase in the Services PMI&nbsp;in October was driven by boosts of more than 4 percentage points for both the Employment and Supplier Deliveries indexes. The Business Activity and New Orders indexes both dropped by at least 2 percentage points. Each of the four subindexes are now above their averages for 2024,&#8221; stated Steve Miller, chair of the ISM Services Business Survey Committee, said.
<h3 class="wp-block-heading">ISM Services PMI For October: Key Highlights</h3>
<ul>
<li>The subindex for Business Activity eased from 59.9% to 57.2% in October.</li>
<li>The subindex for New Orders eased from 59.4% to 57.4% in October. </li>
<li>The subindex for Prices eased from 59.4% to 58.1%. </li>
<li>The subindex for Employment rose from 48.1% to 53%, well above the expected 48%. The outcome marked the highest level in employment index since September 2023. </li>
</ul>
&#8220;Concerns over political uncertainty were again more prevalent than the previous month. Impacts from hurricanes and ports labor turbulence were mentioned frequently, although several panelists mentioned that the longshoremen's strike had less of an impact than feared due to its short duration,&#8221; Miller added. 
<h3 class="wp-block-heading">Market Reactions</h3>
On Tuesday, U.S. stocks rebounded as investors reacted positively to the latest ISM Services PMI data, alleviating earlier political concerns as Americans headed to the polls to elect the 47th president.
The S&amp;P 500, represented by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), rose 0.8%. The tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), rallied nearly 1%, while the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) edged 0.6% higher.
Yields on 10-year Treasury bonds rose 7 basis points to 4.36%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.5%. 
The U.S. dollar index — as tracked by the  Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) — weakened 0.5%.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

US Services Sector Gauge Rises More Than Expected To Over 2-Year Highs As Employment Index Defies Hurricane Shocks

Cushman & Wakefield shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Andean Precious Metals Corp (APM) is up 1040.96% today. APM has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on APM!See Full APM ReportAPM stock closed at $0.83 and is up $8.64 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as mo

Should You Hold Andean Precious Metals Corp (APM) Stock Wednesday Morning?

JAGX and GNPX among Health Care movers

XTIA, PSNL and LIDR among mid-day movers

Andean Precious Metals Corp (APM) has gained Wednesday morning, with the stock increasing 888.10% in pre-market trading to 8.3. APM's short-term technical score of 55 indicates that the stock has traded more bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 100 out o

Andean Precious Metals Corp (APM) has risen 888.10% Wednesday In Premarket Trading

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. 



Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.



But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.



Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.



While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. 



For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. 



As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.



We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.



The U.S.-based company in this equation is Eli Lilly &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.



The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div>The European entry into this equation is Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.



Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.



Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.



NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.



NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div>Corbus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.



The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.



Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.



Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.



Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Aptorum Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/">APM</a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. 



Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.



The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and YOOV Group, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.



Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.



News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div>Merck &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.



But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.



Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.



Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with Daiichi Sankyo to jointly develop three cancer treatments.



MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Gyre Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/">GYRE</a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. 



The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.



It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.



The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.



Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.



GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>Neurogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/">NGNE</a>) is a biotech company that is developing what it calls EXACT gene therapy technology. 



The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.



It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.



The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.



That gives it a solid window to develop and get approvals.



NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

CGC, GENE and HOLO among mid-day movers

Aptorum Group (APM) has released an update. Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the f...

Aptorum Group Reports Decreased Annual Loss

Aptorum Group reports FY results

Aptorum Group (APM) has released an update. Aptorum Group Limited has announced an amendment to extend the term of its Merger Agreement with YOOV G...

Aptorum Group Extends Merger Agreement Term

Aptorum Group (APM) has released an update. Aptorum Group Limited announced the resignation of two directors, Dr. Mirko Scherer and Mr. Charles Bat...

Aptorum Group Board Sees Key Resignations

AILE

AISP

ALRN

ANGH

ANVS

APAC

AQST

BNTC

BPTH

CRBP

EDBL

FEMY

GENE

GNPX

GYRE

HOLO

ICLK

INLX

JAGX

LFCR

LIDR

MIGI

NGNE

NRXP

PSNL

RETO

RLMD

SINT

SWVL

TFFP

THCH

TOON

TRUG

TSHA

WISA

WORX

WULF

XPON

XTIA

XTLB

Press Releases

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Comments

Aptorum Gr

Aptorum Gr (APM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO